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Background: Percutaneous radiofrequency ablation (RFA) is a well-established local treatment for small
hepatocellular carcinoma (HCC). However, poor differentiation is a risk factor for tumor seeding or intrahepatic
dissemination after RFA for HCC. The present study aimed to develop a method for predicting poorly differentiated
HCC using contrast computed tomography (CT) for safe and effective RFA.
Methods: Of HCCs diagnosed histologically, 223 patients with 226 HCCs showing tumor enhancement on contrast
CT were analyzed. The tumor enhancement pattern was classified into two categories, with and without non-enhanced
areas, and tumor stain that disappeared during the venous or equilibrium phase with the tumor becoming hypodense
was categorized as positive for washout.
Results: The 226 HCCs were evaluated as well differentiated (w-) in 56, moderately differentiated (m-) in 137, and poorly
differentiated (p-) in 33. The proportions of small HCCs (3 cm or less) in w-HCCs, m-HCCs, and p-HCCs were 86% (48/56),
59% (81/137), and 48% (16/33), respectively. The percentage with heterogeneous enhancement in all HCCs was 13% in
w-HCCs, 29% in m-HCCs, and 85% in p-HCCs. The percentage with tumor stain washout in the venous phase was 29%
in w-HCCs, 63% in m-HCCs, and 94% in p-HCCs. The percentage with heterogeneous enhancement in small HCCs was
10% in w-HCCs, 10% in m-HCCs, and 75% in p-HCCs. The percentage with tumor stain washout in the venous phase in
small HCCs was 23% in w-HCCs, 58% in m-HCCs, and 100% in p-HCCs. Significant correlations were seen for each
factor (p < 0.001 each). Sensitivity, specificity, positive predictive value, negative predictive value, and accuracy for
prediction of poor differentiation in small HCCs by tumor enhancement with non-enhanced areas were 75%, 90%,
48%, 97%, and 88%, respectively; for tumor stain washout in the venous phase, these were 100%, 55%, 22%, 100%,
and 60%, respectively.
Conclusions: Tumor enhancement patterns were associated with poor histological differentiation even in small
HCCs. Tumor enhancement with non-enhanced areas was valuable for predicting poorly differentiated HCC.
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Percutaneous radiofrequency ablation (RFA) is a well-
established local treatment for unresectable small hepa-
tocellular carcinoma (HCC), which is a repeatable and
safe procedure. Currently, RFA is considered the standard
of care for patients with Barcelona-Clinic Liver Cancer
(BCLC) 0-A tumors not suitable for surgery [1]. Recently,
Forner et al. [2] proposed RFA instead of resection in pa-
tients with very early (<2 cm) HCC.* Correspondence: tamahide@wakayama-med.ac.jp
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unless otherwise stated.However, several investigators have reported the risk
of seeding [3-5], intrahepatic dissemination [6,7], and ag-
gressive recurrence after RFA [8-10]. Some investigators
reported that these critical recurrences were related to
poor differentiation [4,7]. Therefore, poor differentiation
would be a risk factor for tumor seeding or intrahepatic
dissemination after RFA for HCC. Furthermore, the
prognosis of patients with poorly differentiated HCCs
is worse even with radical therapy [11-13]. Along with
de-differentiation from well to moderately/poorly dif-
ferentiated HCC, even small HCCs have a greater ten-
dency for vascular invasion and intrahepatic metastasisl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Correlation between tumor enhancement pattern




Well Moderately Poorly p-value
All HCCs n = 56 n = 137 n = 33
With non-enhanced
areas (n = 74)
7 (13%) 39 (29%) 28 (85%)
Without non-enhanced
areas (n = 152)
49 (88%) 98 (72%) 5 (15%) <0.001
Small HCCs (3 cm or less) n = 48 n = 81 n = 16
With non-enhanced
areas (n = 25)
5 (10%) 8 (10%) 12 (75%)
Without non-enhanced
areas (n = 120)
43 (90%) 73 (90%) 4 (25%) <0.001
HCC, hepatocellular carcinoma.
The p-value was calculated among each differentiation group by with versus
without non-enhanced area using Fisher’s exact test.
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atic function is well preserved, hepatic resection should be
the first choice for local control, especially in cases of
moderately to poorly differentiated HCC. Therefore, the
prediction of poorly differentiated HCC before therapy is
crucial for deciding the optimal therapeutic strategy and
for safe and effective RFA even for small HCCs.
Contrast computed tomography (CT) is commonly used
for definite diagnosis of HCCs on imaging [17]. However,
the differential diagnosis of poorly differentiated HCC using
contrast CT has not been sufficiently established. In the
present study, correlations between the enhancement
pattern on contrast CT and histological differentiation,
and the ability to predict poorly differentiated HCC using
contrast CT were analyzed.
Results
Correlation of tumor size and histological differentiation
The histological classification was w-HCC in 56, m-HCC
in 137, and p-HCC in 33. Mean diameter by histological
classification was 26 ± 13 mm in w-HCCs, 33 ± 20 mm in
m-HCCs, and 44 ± 33 mm in p-HCCs. The tumor size
was significantly larger as the histological differentiation
grade advanced (p = 0.03). In pairwise comparisons, tumor
size was significantly smaller for w-HCCs than for m-HCCs
and p-HCCs (P = 0.003 and p = 0.001). However, there was
no significant difference between m-HCCs and p-HCCs
(p = 1.000). The proportions of small HCCs (3 cm or less)
in w-HCCs, m-HCCs, and p-HCCs were 86% (48/56), 59%
(81/137), and 48% (16/33), respectively. The proportions of
w-HCCs, m-HCCs, and p-HCCs in small HCCs were 33%
(48/145), 56% (81/145), and 11% (16/145), respectively.
Correlation between tumor enhancement patterns and
histological differentiation
The correlation between tumor enhancement patterns
in the arterial phase and histological differentiation is
shown in Table 1. The percentage of tumors with tumor
stain with non-enhanced areas was significantly higher as
the histological differentiation grade advanced (p < 0.001).
In pairwise comparisons, there was a significant difference
between m-HCCs and p-HCCs. However, there was no
significant difference between w-HCCs and m-HCCs. As
in all HCCs, there was also a significant correlation even
in small HCCs (3 cm or less in diameter).
Correlation between tumor stain washout and
histological differentiation
The correlation between tumor stain washout in the
venous phase and histological differentiation is shown
in Table 2. The percentage of tumors with tumor stain
washout in the venous phase was significantly higher as
the histological differentiation grade advanced (p < 0.001).
In pairwise comparisons, there were significant differencesamong all groups (p < 0.05). As in all HCCs, there were
also significant correlations even in small HCCs.
The correlation between tumor stain washout in the
equilibrium phase and histological differentiation is shown
in Table 3. The percentage of tumors with tumor stain
washout in the equilibrium phase was higher as the histo-
logical differentiation grade advanced (p < 0.001). However,
in comparisons of each pair, no significant difference was
observed between m-HCCs and p-HCCs. As in all HCCs,
there were also significant correlations even in small HCCs
between tumor stain washout in the equilibrium phase and
histological differentiation.
Sensitivity, specificity, positive predictive value, negative
predictive value, and accuracy for the prediction of
poorly differentiated HCC
Sensitivity, specificity, PPV, NPV, and accuracy for the
prediction of p-HCC by each CT finding are shown in
Table 4. Sensitivity for p-HCC was inferior by tumor
enhancement with non-enhanced areas than by tumor
stain washout in the venous phase. However, specificity and
accuracy for p-HCC were superior by tumor enhancement
with non-enhanced areas than by tumor stain washout
in the venous phase. These findings were seen even in
small HCCs. Although accuracies for p-HCC in both all
HCCs and small HCCs were slightly improved by the
combination of tumor enhancement with non-enhanced
areas and tumor stain washout in the venous phase,
these improvements were not significant.
Discussion
With respect to a hemodynamic change from m-HCC to
p-HCC, Asayama et al. [18] reported that the arterial blood
supply decreases significantly. Furthermore, it was also
found that, although hypervascular tumor was predom-
inant in p-HCCs, the proportion of hypovascular tumors
Table 2 Correlation between tumor stain washout in the
venous phase and histological differentiation
Tumor stain washout
in the venous phase
Histological differentiation
Well Moderately Poorly p-value
All HCCs n = 56 n = 137 n = 33
Positive (n = 133) 16 (29%) 86 (63%) 31 (94%)
Negative (n = 93) 40 (71%) 51 (37%) 2 (6%) <0.001
Small HCCs (3 cm or less) n = 48 n = 81 n = 16
Positive (n = 74) 11 (23%) 47 (58%) 16 (100%)
Negative (n = 71) 37 (77%) 34 (42%) 0 (0%) <0.001
HCC, hepatocellular carcinoma.
The p-value was calculated among each differentiation group by positive
versus negative tumor stain washout using Fisher’s exact test.
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on contrast ultrasonography [19] and contrast CT [20].
However, Jang et al. [19] indicated that there was no
significant difference in arterial vascularity between
w-HCCs and p-HCCs on contrast ultrasonography.
Lee et al. [20] also demonstrated that no significant
difference was seen in the prevalence of atypical arterial en-
hancement such as hypoattenuation between w-HCCs and
p-HCCs on contrast CT. These studies did not analyze the
diagnostic values for p-HCC using arterial hypovascularity.
Sanda et al. [21] demonstrated that even small HCCs
(diameter up to 2 cm) intermingled with hypovascular
areas and hypervascular areas on the arterial phase of
contrast CT showed contiguous multinodular type and
included p-HCC components. Kawamura et al. [22] re-
ported that heterogeneous enhancement with irregular
ring-like structures in the arterial phase of contrast CT
is a significant independent predictor of p-HCC. Of course,
their heterogeneous enhancement pattern with irregular
ring-like structures was included in the criteria of tumor
enhancement with non-enhanced areas in the present study.
From the above, it is assumed that a hemodynamic change
from hypervascularity to hypovascularity in overt HCCTable 3 Correlation between tumor stain washout in the
equilibrium phase and histological differentiation
Tumor stain washout in
the equilibrium phase
Histological differentiation
Well Moderately Poorly p-value
All HCCs n = 56 n = 137 n = 33
Positive (n = 197) 39 (70%) 125 (91%) 33 (100%)
Negative (n = 29) 17 (30%) 12 (9%) 0 (0%) <0.001
Small HCCs (3 cm or less) n = 48 n = 81 n = 16
Positive (n = 118) 32 (67%) 70 (86%) 16 (100%)
Negative (n = 27) 16 (33%) 11 (14%) 0 (0%) 0.003
HCC, hepatocellular carcinoma.
The p-value was calculated among each differentiation group by positive
versus negative tumor stain washout using Fisher’s exact test.means that p-HCC components have been generated
in the HCC. Accordingly, the present arterial tumor
enhancement classification with or without non-enhanced
areas is reasonable for predicting hypervascular HCC
including p-HCC components.
With respect to other enhancement pattern findings of
contrast CT associated with p-HCC, tumor stain washout
in the venous phase has been reported. Nishie et al. [23]
indicated that p-HCCs are considered to show faster
tumor stain washout on contrast CT than non-p-HCCs.
On contrast magnetic resonance imaging, it has also been
reported that tumor stain washout in the venous phase was
more frequently seen in p-HCCs [24,25]. Furthermore, on
contrast-enhanced ultrasonography, tumor stain washout
time was significantly less in p-HCCs [19,26]. From the
various above contrast studies and the present results,
there is no doubt that tumor stain washout becomes fas-
ter as the histological differentiation of HCC advances.
In the present study, the diagnostic accuracy for p-HCC
using tumor enhancement with non-enhanced areas in the
arterial phase of contrast CT was high even in small HCCs.
On the other hand, the accuracy for p-HCC by tumor stain
washout in the venous phase of contrast CT was not as
high. In the present results, tumor enhancement with non-
enhanced areas and tumor stain washout in the venous
phase were associated with poor histological differentiation
even in small HCCs. However, the improvement of accur-
acies for p-HCC in both all HCCs and small HCCs by the
combination of tumor enhancement with non-enhanced
areas and tumor stain washout in the venous phase were
slight, and these improvements were not significant. There-
fore, tumor enhancement with non-enhanced areas appears
to be the most valuable finding on contrast CT in the pre-
diction of poorly differentiated HCC.
The present study had some limitations. First, the present
study was retrospective. Furthermore, HCCs with no
enhancement in the arterial phase of contrast CT were
not evaluated. Therefore, the present results cannot be
generalized to HCCs without arterial enhancement on
contrast CT. Second, needle biopsy samples were used.
The assessment of histological differentiation grade using
biopsy samples may not reflect the lowest differentiated
component in the tumor. Nevertheless, the present results
could suggest that the contrast CT enhancement pattern
facilitates assessment of histological malignant potential.
Third, this study could not show the correlation between
the contrast CT enhancement pattern and the prognosis.
Kawamura et al. [27] reported that a heterogeneous en-
hancement pattern with irregular ringed-like structures
on dynamic CT is associated with tumor recurrence after
RFA. However, their study was very small. In the future,
a large-scale cohort study should be conducted to inves-
tigate whether these findings will contribute to predict-
ing outcome after RFA.
Table 4 Sensitivity, specificity, positive predictive value,
negative predictive value, and accuracy of prediction
for poorly differentiated hepatocellular carcinoma
using CT findings




85% 76% 34% 97% 77%
Tumor stain washout
in the venous phase
94% 47% 23% 98% 54%
Both findings positive 79% 80% 40% 96% 80%
Small HCCs (3 cm or less)
Enhancement with
non-enhanced area
75% 90% 48% 97% 88%
Tumor stain washout
in the venous phase
100% 55% 22% 100% 60%
Both findings positive 75% 92% 55% 97% 90%
CT, computed tomography; PPV, positive predictive value; NPV, negative
predictive value; HCC, hepatocellular carcinoma.
Table 5 Patients’ characteristics
Age (years; mean ± SD) 68.3 ± 8.2
Sex (male/female) 147/76
Etiology (HCV/non-HCV) 172/51
Tumor size (mm; mean ± SD) 33 ± 22
Number of tumors (mean ± SD) 1.7 ± 1.2
AFP (ng/mL; mean ± SD) 3026.6 ± 35190.2
AFP-L3 (%; mean ± SD) 14.5 ± 24.7
DCP (mAU/mL; mean ± SD) 4130.0 ± 23805.1
Child class (A/B/C) 161/55/7
Activity stage (A0/1/2/3) 11/99/98/15
Fibrosis grade (F0/1/2/3/4) 7/21/39/68/88
SD, standard deviation; HCV, hepatitis C virus; AFP, alpha-fetoprotein; AFP-L3,
lens culinaris agglutinin-reactive alpha-fetoprotein;
DCP, Des-gamma-carboxyprothrombin.
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In conclusion, arterial tumor enhancement with non-
enhanced areas and tumor stain washout in the venous
phase were associated with poor histological differentiation
even in small HCCs, and tumor enhancement with non-
enhanced areas was the most valuable finding in the
prediction of poorly differentiated HCC. For safe and ef-
fective RFA for small HCCs, systematic resection should
be considered as the treatment of first choice for small
HCCs with arterial tumor enhancement with non-enhanced
areas, because the prevalence of microscopic vascular inva-
sion or intrahepatic metastasis is quite high in p-HCCs. If
unresectable, combinations of RFA with transcatheter arter-
ial chemo-embolization should be considered as alternativeYes
HCC database between May 2001 and Dec
249 patients with 252 HCCs
Yes
No 2
229 patients with 232 HCCs
No
Y
Nodule in nodule type or mixed type?
223 patients with 226 HCCs
310 patients with 315 HCCs histologically d
Having plain and tri-phasiccontrast CT with
two months before histological diagnosis?
Arterial enhancement positive?
Figure 1 Patient enrollment flowchart.treatment strategies. However, further study and analysis are
required to determine whether this approach actually helps
improve the prognosis of small p-HCCs.
Methods
Patients
In our hospital’s HCC database, 310 patients with 315
HCC nodules were histologically diagnosed by tumor
biopsy or surgical resection between May 2001 and
December 2010. The flowchart of patient enrollment
is shown in Figure 1. Of 226 HCC nodules, 165 were
diagnosed by tumor biopsy, and 61 were diagnosed by
resection. The patients’ characteristics are summarized in
Table 5. This retrospective study was approved by our eth-
ics committee and conformed to the Helsinki Declaration.
The need for patients to give written, informed consent
was waived by our ethics committee.ember 2010
61 patients with 63 HCCs
No
0 patients with 20 HCCs
es
6 patients with 6 HCCs
iagnosed 
HCC: hepatocellular carcinoma 
CT: computed tomography
in
Figure 2 Tumor enhancement without non-enhanced areas. The pre-contrast image (a) shows an iso-density tumor. In comparison with
pre-contrast image, the tumor stain has no non-enhanced areas in the arterial phase (b). The tumor is indicated by arrows.
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All contrast CT examinations were performed with
multi-detector row CT scanners having at least 4 detectors
(Aquilion, Toshiba Medical Systems, Tochigi, Japan or Light
speed VCT, GE Medical Systems, Milwaukee, WI, USA)
with a section thickness of 5 mm. In addition to plain
images, arterial phase images were obtained 40 seconds
after the start of bolus administration. From 2005 on-
ward, the arterial phase was scanned with an automatic
bolus-tracking program. Venous and equilibrium phase
images were obtained at 70 seconds and 180 seconds,
respectively. All patients received a non-ionic iodinated
contrast medium at a dose of 580 mgI/kg; it was admin-
istered to all patients by an automated power injector
for 30 seconds (19.3 mgI/kg/s).
Contrast CT findings related to tumor enhancement
pattern and washout were categorized as follows. Tumor
enhancement pattern in the arterial phase was classified
into two categories, with and without non-enhanced areas
(Figures 2 and 3). Tumor stain obtained during the arterial
phase that disappeared during the venous or equilibrium
phase, with the tumor becoming hypodense, was catego-
rized as positive for washout. Images obtained by contrast
CT were independently analyzed using the above criteria
of enhancement patterns without reference to histological
differentiation by two experienced readers with more thanFigure 3 Tumor enhancement with non-enhanced areas. The pre-cont
pre-contrast image, the tumor stain has non-enhanced areas in the arterial20 years of experience in liver imaging. Any disagreements
in interpretation were resolved by consensus.
Needle biopsies of tumors were performed using an
18-gauge needle (Bard Monopty® C.R. Bard Inc., Covington,
GA, USA). Liver biopsy was performed using a 16-gauge
needle. Histological findings were classified using the
METAVIR scoring system [28]. All biopsy and resected
specimens were examined by two experienced pathologists,
without reference to the CT findings of their tumors and
surrounding livers. According to the International Working
Party classification [29], HCC histology was classified into
three types: well differentiated (w-), moderately differenti-
ated (m-), and poorly differentiated (p-) HCCs. If heteroge-
neous differentiation was found in the obtained HCC
tissue, differentiation grade was classified based on the low-
est differentiated grade. Any discrepancies between the two
pathologists with more than 20 years of experience in liver
pathology were resolved by discussion to reach consensus.
Statistical analysis
Values are expressed as means ± standard deviation (SD).
The correlation between tumor size and histological dif-
ferentiation was analyzed using the Jonckheere-Terpstra
test. The correlation between the enhancement pat-
tern and histological differentiation was analyzed using
Fisher’s exact test or the chi-square test of independence.rast image (a) shows a low-density tumor. In comparison with the
phase (b). The tumor is indicated by arrows.
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http://www.cancerimagingjournal.com/content/14/1/7Sensitivity, specificity, positive predictive value (PPV), nega-
tive predictive value (NPV), and accuracy for diagnosis of
p-HCC were calculated according to findings on contrast
CT. Accuracy between groups was compared using the
McNemar test. A p value less than 0.05 was considered
significant. All analyses were performed using the SPSS
20.0 software package (SPSS, Inc., Chicago, IL, USA).
Abbreviations
HCC: Hepatocellular carcinoma; RFA: Percutaneous radiofrequency ablation;
CT: Computed tomography; BCLC: Barcelona-clinic liver cancer; w: Well
differentiated; m: Moderately differentiated; p: Poorly differentiated; SD: Standard
deviation; PPV: positive predictive value; NPV: Negative predictive value.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
NK, TH and IM designed and proposed the research; all authors approved
the analysis and participated in drafting the article; MY, SN, MK, DH, UK, II,
MT, IM, and KJ collected the clinical data; TH and IM analyzed imaging
examinations; NK and TH performed the statistical analysis; NK and TH wrote
the manuscript. All authors read and approved the final manuscript.
Received: 3 November 2013 Accepted: 27 January 2014
Published: 22 April 2014
References
1. European Association For The Study Of The Liver, European Organisation For
Research and Treatment Of Cancer: EASL-EORTC clinical practice guidelines:
management of hepatocellular carcinoma. J Hepatol 2012, 56:908–943.
2. Forner A, Llovet JM, Bruix J: Hepatocellular carcinoma. Lancet 2012,
379:1245–1255.
3. Llovet JM, Vilana R, Bru C, Bianchi L, Salmeron JM, Boix L, Ganau S, Sala M,
Pages M, Ayuso C, Sole M, Rodes J, Bruix J: Increased risk of tumor
seeding after percutaneous radiofrequency ablation for single
hepatocellular carcinoma. Hepatol 2001, 33:1124–1129.
4. Imamura J, Tateishi R, Shiina S, Goto E, Sato T, Ohki T, Masuzaki R, Goto T,
Yoshida H, Kanai F, Hamamura K, Obi S, Omata M: Neoplastic seeding after
radiofrequency ablation for hepatocellular carcinoma. Am J Gastroenterol
2008, 103:3057–3062.
5. Shirai K, Tamai H, Shingaki N, Mori Y, Moribata K, Enomoto S, Deguchi H, Ueda
K, Maekita T, Inoue I, Iguchi M, Yanaoka K, Oka M, Ichinose M: Clinical features
and risk factors of extrahepatic seeding after percutaneous radiofrequency
ablation for hepatocellular carcinoma. Hepatol Res 2011, 41:738–745.
6. Nicoli N, Casaril A, Hilal MA, Mangiante G, Marchiori L, Ciola M, Invernizzi L,
Campagnaro T, Mansueto G: A case of rapid intrahepatic dissemination of
hepatocellular carcinoma after radiofrequency thermal ablation. Am J
Surg 2004, 188:165–167.
7. Mori Y, Tamai H, Shingaki N, Moribata K, Shiraki T, Deguchi H, Ueda K, Enomoto
S, Magari H, Inoue I, Maekita T, Iguchi M, Yanaoka K, Oka M, Ichinose M: Diffuse
intrahepatic recurrence after percutaneous radiofrequency ablation for
solitary and small hepatocellular carcinoma. Hepatol Int 2009, 3:509–515.
8. Seki T, Tamai T, Ikeda K, Imamura M, Nishimura A, Yamashiki N, Nakagawa T,
Inoue K: Rapid progression of hepatocellular carcinoma after transcatheter
arterial chemoembolization and percutaneous radiofrequency ablation in
the primary tumour region. Eur J Gastroenterol Hepatol 2001, 13:291–294.
9. Takada Y, Kurata M, Ohkohchi N: Rapid and aggressive recurrence
accompanied by portal tumor thrombus after radiofrequency ablation
for hepatocellular carcinoma. Int J Clin Oncol 2003, 8:332–335.
10. Ruzzenente A, Manzoni GD, Molfetta M, Pachera S, Genco B, Donataccio M,
Guglielmi A: Rapid progression of hepatocellular carcinoma after
radiofrequency ablation. World J Gastroenterol 2004, 10:1137–1140.
11. Sasaki Y, Imaoka S, Ishiguro S, Nakano H, Kasugai H, Fujita M, Inoue E,
Ishikawa O, Furukawa H, Nakamori S, Kuroda C, Iwanaga T: Clinical
features of small hepatocellular carcinomas as assessed by histologic
grades. Surgery 1996, 119:252–260.12. Oishi K, Itamoto T, Amano H, Fukuda S, Ohdan H, Tashiro H, Shimamoto F,
Asahara T: Clinicopathologic features of poorly differentiated
hepatocellular carcinoma. J Surg Oncol 2007, 95:311–316.
13. Kim SH, Lim HK, Choi D, Lee WJ, Kim MJ, Kim CK, Jeon YH, Lee JM, Rhim H:
Percutaneous radiofrequency ablation of hepatocellular carcinoma:
effect of histologic grade on therapeutic results. AJR Am J Roentgenol
2006, 186:S327–S333.
14. Esnaola NF, Lauwers GY, Mirza NQ, Nagorney DM, Doherty D, Ikai I,
Yamaoka Y, Regimbeau JM, Belghiti J, Curley SA, Ellis LM, Vauthey JN:
Predictors of microvascular invasion in patients with hepatocellular
carcinoma who are candidates for orthotopic liver transplantation.
J Gastrointest Surg 2002, 6:224–232. discussion 232.
15. Nakashima Y, Nakashima O, Tanaka M, Okuda K, Nakashima M, Kojiro M:
Portal vein invasion and intrahepatic micrometastasis in small
hepatocellular carcinoma by gross type. Hepatol Res 2003, 26:142–147.
16. Fukuda S, Itamoto T, Nakahara H, Kohashi T, Ohdan H, Hino H, Ochi M,
Tashiro H, Asahara T: Clinicopathologic features and prognostic factors of
resected solitary small-sized hepatocellular carcinoma. Hepatogastroenterology
2005, 52:1163–1167.
17. Clinical practice guidelines for hepatocellular carcinoma - the Japan
society of hepatology 2009 update. Hepatol Res 2010, 40(Suppl 1):2–144.
18. Asayama Y, Yoshimitsu K, Nishihara Y, Irie H, Aishima S, Taketomi A, Honda H:
Arterial blood supply of hepatocellular carcinoma and histologic grading:
radiologic-pathologic correlation. AJR Am J Roentgenol 2008, 190:W28–W34.
19. Jang HJ, Kim TK, Burns PN, Wilson SR: Enhancement patterns of
hepatocellular carcinoma at contrast-enhanced US: comparison with
histologic differentiation. Radiology 2007, 244:898–906.
20. Lee JH, Lee JM, Kim SJ, Baek JH, Yun SH, Kim KW, Han JK, Choi BI:
Enhancement patterns of hepatocellular carcinomas on multiphasic
multidetector row CT: comparison with pathological differentiation.
Br J Radiol 2012, 85:e573–e583.
21. Sanada Y, Yoshida K, Itoh H: Comparison of CT enhancement patterns
and histologic features in hepatocellular carcinoma up to 2 cm: assessment
of malignant potential with claudin-10 immunohistochemistry. Oncol Rep
2007, 17:1177–1182.
22. Kawamura Y, Ikeda K, Hirakawa M, Yatsuji H, Sezaki H, Hosaka T, Akuta N,
Kobayashi M, Saitoh S, Suzuki F, Suzuki Y, Arase Y, Kumada H: New classification
of dynamic computed tomography images predictive of malignant
characteristics of hepatocellular carcinoma. Hepatol Res 2010, 40:1006–1014.
23. Nishie A, Yoshimitsu K, Okamoto D, Tajima T, Asayama Y, Ishigami K,
Kakihara D, Nakayama T, Takayama Y, Shirabe K, Fujita N, Honda H: CT
prediction of histological grade of hypervascular hepatocellular
carcinoma: utility of the portal phase. Jpn J Radiol 2013, 31:89–98.
24. Enomoto S, Tamai H, Shingaki N, Mori Y, Moribata K, Shiraki T, Deguchi H,
Ueda K, Inoue I, Maekita T, Iguchi M, Yanaoka K, Oka M, Ichinose M:
Assessment of hepatocellular carcinomas using conventional magnetic
resonance imaging correlated with histological differentiation and a
serum marker of poor prognosis. Hepatol Int 2011, 5:730–737.
25. Okamoto D, Yoshimitsu K, Nishie A, Tajima T, Asayama Y, Ishigami K,
Hirakawa M, Ushijima Y, Kakihara D, Nakayama T, Nishihara Y, Aishima S,
Taketomi A, Kishimoto J, Honda H: Enhancement pattern analysis of
hypervascular hepatocellular carcinoma on dynamic MR imaging with
histopathological correlation: validity of portal phase imaging for
predicting tumor grade. Eur J Radiol 2012, 81:1116–1121.
26. Fan ZH, Chen MH, Dai Y, Wang YB, Yan K, Wu W, Yang W, Yin SS: Evaluation of
primary malignancies of the liver using contrast-enhanced sonography:
correlation with pathology. AJR Am J Roentgenol 2006, 186:1512–1519.
27. Kawamura Y, Ikeda K, Seko Y, Hosaka T, Kobayashi M, Saitoh S, Kumada H:
Heterogeneous type 4 enhancement of hepatocellular carcinoma on
dynamic CT is associated with tumor recurrence after radiofrequency
ablation. AJR Am J Roentgenol 2011, 197:W665–W673.
28. Bedossa P, Poynard T: An algorithm for the grading of activity in chronic
hepatitis C. The METAVIR Cooperative Study Group. Hepatol 1996,
24:289–293.
29. Terminology of nodular hepatocellular lesions. International working
party. Hepatol 1995, 22:983–993.
doi:10.1186/1470-7330-14-7
Cite this article as: Nakachi et al.: Prediction of poorly differentiated
hepatocellular carcinoma using contrast computed tomography. Cancer
Imaging 2014 14:7.
